Zevra Therapeutics (ZVRA) reported a Q1 net loss late Tuesday of $0.06 per diluted share, narrowing from the loss of $0.40 a year earlier.
Analysts polled by FactSet expected a loss of $0.19.
Net revenue in the three months ended March 31 rose to $20.4 million from $3.43 million a year earlier.
Analysts surveyed by FactSet expected $16.9 million.
Zevra shares rose 4.8% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。